Articles database
 
 
Web AnyArticles.com
Browse by Category:
  Health and Fitness >
  Subcategories
Acne Acne (413)
Aerobics Cardio Aerobics Cardio (70)
Alternative Alternative (1277)
Beauty Beauty (1127)
Build Muscle Build Muscle (396)
Depression Depression (383)
Diabetes Diabetes (188)
Exercise Exercise (565)
Fitness Equipment Fitness Equipment (386)
Hair Loss Hair Loss (305)
Medicine Medicine (640)
Meditation Meditation (151)
Men Issues Men Issues (315)
Nutrition Nutrition (1092)
Supplements Supplements (645)
Weight Loss Weight Loss (2187)
Women Issues Women Issues (481)
Yoga Yoga (209)


  Categories :
 
  Arts and Entertainment
  Automotive
  Business
  Communications
  Computers and Technology
  Finance
  Food and Drink
  Health and Fitness
  Home and Family
  Home Based Business
  Internet and Businesses Online
  Kids and Teens
  Legal
  News and Society
  Recreation and Sports
  Reference and Education
  Self Improvement
  Shopping and Product Reviews
  Travel and Leisure
  Womens Interests
  Writing and Speaking
  Random Category
  Advertising
  Society
  Diabete
Weight Loss article : A new approval of UK’s National Institute for Health and Clinical Excellence (NICE)
 

Health and Fitness > Weight Loss > A new approval of UK’s National Institute for Health and Clinical Excellence (NICE)

0 Reviews [ add review ], Article rating : 0.00, 0 votes. Author : Scott

On the 26th March, Sanofi-Aventis, the third largest pharmaceutical manufacturer in the world, announced that the UK’s National Institute for Health and Clinical Excellence (NICE), had approved Acomplia for use in the National Health Service (NHS). NICE is a non-governmental organisation. It plays the role of a gatekeeper and, if it approves a medication, its use in the NHS is subsidised out of public funds. Up to now, Acomplia has had approval granted by the European Medicines Agency (EMEA) for use on private prescription only. So patients have had to pay the full retail price for Acomplia. This decision by NICE means that patients who have a BMI of 30 or more, or a BMI of 27 with associated risk factors, can now get treatment without having to pay for Acomplia (the change of diet and the introduction of physical exercise have no additional cost implications). This is a small step forward for Sanofi-Aventis which has a good product but has found it difficult to promote its use.

Because of the reluctance of regulatory authorities to add a “weight loss” medication to the list of approved medications, the sales of Acomplia have been only modest (around $120m last year). Relatively this is a good performance because European patients have been buying this product out of their own pockets. Nevertheless, it is disappointing that such a good product as Acomplia cannot be more widely accepted. For example, the German regulatory authority has refused to reimburse patients out of public funds because it views Acomplia as a lifestyle product.

This starkly contrasts with the public policy stance of the British government which has made the fight against obesity in the young one of its top medical priorities. This is a particularly positive move towards preventative medicine by a country that believes it is facing an “obesity crisis”. The more overweight you get, the greater the risks of heart disease or diabetes. Both of these represent long-term and expensive conditions to treat in a public health system. It is therefore good value for money to get as many as possible to use Acomplia and reduce their weight while young.

In the United states, the Food and Drug Administration has been reluctant to give any recognition to Acomplia after a link was made to one or two very rare cases in which individuals who happened to be taking Acomplia attempted suicide. So far, there is no clinical evidence to support a general link between Acomplia and suicide. More clinical trials are underway and Sanofi-Aventis expects to have new evidence to submit to the FDA in 2009. But this experience with Acomplia has become increasingly common. Many new and effective medications have been approved for the European market but have not received FDA approval. Several European manufacturers have indicated that they may ignore the US market in future even though it is the largest in the world. They all complain that the FDA’s demands for more and more clinical data prior to approval has become unreasonable.

It is not clear why the FDA has grown more demanding. It may be that the process has become more political in the US after the approval of Vioxx became the focus of litigation and hearings on Capitol Hill. There are also funding problems as the agency struggles to consider more applications for approval with a reducing budget. As it is, US television and print media are full of advertisements for medications. This is the land of the hard sell. Europe does not permit national advertising campaigns for prescription medications. In one sense, this makes Acomplia’s market penetration in Europe all the more impressive. Positive word-of-mouth has been selling the product. Thus, if you live in the UK, you can enjoy the benefits of Acomplia to reduce your weight on the NHS. Elsewhere, you can pay for this product confident that, in conjunction with a low calorie diet and physical exercise, it will significantly reduce your weight.


0 Reviews [ add review ], Article rating : 0.00, 0 votes. Author : Scott
Rate this story : and read/post review(s)


Article reviews



Post your review
[ Note : no HTML/URLs - will removed automatically ]
Your name
Your comments


More articles from Health and Fitness > Weight Loss

Add article | Manage Articles | Top Rated articles | Most Reviewed articles | Contact us | Links